LGM
LCTX icon

Logos Global Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Logos Global Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,000,000
Closed -$4.53M – 62
2024
Q3 		$4.53M Buy
5,000,000
+300,000
+6% +$278K 0.49% 43
2024
Q2 		$4.69M Sell
4,700,000
-1,550,000
-25% -$1.71M 0.38% 44
2024
Q1 		$9.25M Buy
+6,250,000
New +$7.09M 0.75% 35

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Logos Global Management's LCTX Position: Q4 2024 in Review

Logos Global Management sold out of Lineage Cell Therapeutics (LCTX) in Q4 2024, closing a stake of 5,000,000 shares — an estimated $4.53M sold.

Logos Global Management first reported a position in LCTX in Q1 2024 and held it in 3 quarters. The position peaked at $9.25M in Q1 2024. 126 funds tracked by Wall St. Rank hold LCTX as of Q4 2024.

  • Logos Global Management reported no remaining Lineage Cell Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Logos Global Management sold 5,000,000 Lineage Cell Therapeutics shares in Q4 2024, an estimated $4.53M.
  • Logos Global Management first reported a position in Lineage Cell Therapeutics in Q1 2024 and held it in 3 quarters.
  • Logos Global Management's Lineage Cell Therapeutics position peaked at $9.25M in Q1 2024.
  • 126 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2024.

Based on Logos Global Management's 13F filing for Q4 2024, filed 14 Feb 2025.